Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: hCRF Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study

NCT03142893
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill, Ganirelix, Dexamethasone, Dexamethasone Injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone, Hydrocortisone Injection, Gonadorelin, Corticorelin, Placebo oral capsule, Saline Solution, Saline Solution for Injection
Drug
Lead sponsor
Peter y. Liu
Other
Eligibility
22 Years to 45 Years · Male only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 5:29 PM EDT
Withdrawn Phase 3 Interventional

XERECEPT® (hCRF) for Primary Glioma Patients Requiring Dexamethasone to Treat Peritumoral Brain Edema

NCT00226668
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Newport Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2008 · Synced Oct 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency

NCT00001180
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
Interventions
Ovine Corticotropin-Releasing Hormone (oCRH)
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
2,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1982 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

NCT03613129
View directory record Official record
Conditions
Myalgic Encephalomyelitis, Chronic Fatigue Syndrome
Interventions
CT38
Drug
Lead sponsor
LUCINDA BATEMAN, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 21, 2026, 5:29 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia

NCT01373372
View directory record Official record
Conditions
Functional Dyspepsia
Interventions
Acthrel
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures

NCT01673087
View directory record Official record
Conditions
Stress
Interventions
Metyrapone, Dexamethasone, Cortrosyn, Corticorelin ovine triflutate
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 50 Years
Enrollment
256 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 21, 2026, 5:29 PM EDT
Recruiting Not applicable Interventional

Reducing Pregnancy Risks: The Mastery Lifestyle Intervention

NCT05012072
View directory record Official record
Conditions
Mental Health Wellness 1, Preterm Birth
Interventions
The Mastery Lifestyle Intervention
Behavioral
Lead sponsor
Microgen LLC
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

CRF1 Antagonist GSK561679 in Alcoholism

NCT01187511
View directory record Official record
Conditions
Alcohol Dependence
Interventions
GSK561679, Placebo
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Xerecept Intravenous Dose Escalation in Japanese and Caucasian Volunteers

NCT00820092
View directory record Official record
Conditions
Edema
Interventions
Xerecept 1.0, Xerecept 2.0, Xerecept 3.0
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
20 Years to 45 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome

NCT00001453
View directory record Official record
Conditions
Cushing's Syndrome
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 75 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of GSK561679 in Women With Post-Traumatic Stress Disorder

NCT01018992
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
GSK561679, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years · Female only
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
San Francisco, California • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 21, 2026, 5:29 PM EDT
Terminated Phase 1Phase 2 Interventional

Tolerability Study of Xerecept® in Pediatric Patients

NCT01369121
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
XERECEPT
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 21, 2026, 5:29 PM EDT
Withdrawn Phase 1 Interventional

Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia

NCT02349503
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
NBI-77860
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
12 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
2
States / cities
Ann Arbor, Michigan • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Oct 21, 2026, 5:29 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

NCT04037605
View directory record Official record
Conditions
Sleep Restriction
Interventions
Ketoconazole Pill (also known as nizoral), Ganirelix, Dexamethasone Pill, Dexamethasone injection, Cosyntropin Injectable Product, Recombinant Human Luteinizing Hormone (also known as luveris), Hydrocortisone Injection (also known as solu-cortef), Gonadorelin (also known as Lutrepulse), Corticorelin (also known as Acthrel), Placebo oral tablet, Saline Solution, Saline solution for injection
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
60 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

Stress, Hypothalamic-pituitary-adrenal (HPA) Dysfunction, and Relapse in Alcoholism

NCT00744588
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Oct 21, 2026, 5:29 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Dynamics of Leptin and Endocrine Function

NCT00001543
View directory record Official record
Conditions
Healthy, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 21, 2026, 5:29 PM EDT
Completed No phase listed Observational

Gender and Neural Substrates of Stress and Craving

NCT00756925
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Acthrel
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Does Fluoxetine Have an Effect on the CNS CRF Systems in Women Abused in Childhood?

NCT00208897
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Fluoxetine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 21, 2026, 5:29 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effect of Sulfasalazine on CRH Levels in Pregnant Women

NCT05703425
View directory record Official record
Conditions
Preterm Birth
Interventions
Sulfasalazine
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Early Phase 1 Interventional

Effects of Hormone Stimulation on Brain Scans for Cushing s Disease

NCT01459237
View directory record Official record
Conditions
Pituitary Neoplasm
Interventions
Acthrel
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
8 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors

NCT00088166
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF, placebo hCRF
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
27
States / cities
Phoenix, Arizona • Fresno, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

CRF - Nociceptin Receptor Interactions

NCT03302416
View directory record Official record
Conditions
Healthy
Interventions
Hydrocortisone, [C-11]NOP-1A
Drug · Radiation
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 40 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies

NCT00226655
View directory record Official record
Conditions
Brain Edema, Brain Tumor
Interventions
hCRF [XERECEPT (corticorelin acetate injection)]
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
25
States / cities
Phoenix, Arizona • Newport Beach, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2012 · Synced Oct 21, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Alcohol and Gender Effects on Stress Circuit Function

NCT00226694
View directory record Official record
Conditions
Alcoholism, Stress, Alcohol Dependence
Interventions
Citalopram, Placebo
Drug · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Oct 21, 2026, 5:29 PM EDT